C-Scan is the first and only preparation-free test to detect precancerous polyps and enable early intervention and cancer prevention.
More than one third of the U.S. screening age population avoids standard screening procedures such as colonoscopy. C-Scan has the potential to offer a more patient-friendly option, enabling people to get the screening they need.
How does C-Scan work?
Once the ingestible capsule C-Scan Cap is swallowed, it travels naturally along the gastrointestinal tract while scanning the inner lining of the colon. C-Scan Cap actively communicates with the second element of the system, C-Scan Track, which records and stores the scanning data. When the screening procedure is over, C-Scan Cap will be excreted naturally, the patient is notified, and the scanning data can be analyzed by using our proprietary software, C-Scan View.
- Ingestible capsule
- Emission of ultra-low dose X-ray beams
- Scanning of gastrointestinal tract
- Autonomous and natural passage through the gastrointestinal tract
- Total X-ray exposure dose similar to that of a single chest radiography
- Three miniaturized patches worn on the patient’s back
- Integrated positioning, control and recording system
- Continuous recording and storage of C-Scan Cap’s information
- Cloud based analysis suite allows physicians to analyze data anywhere
- Construction of maps of the inner surface of the colon
- Pre-analysis and bookmarking of suspicious findings by an expert technician
The C-Scan’s technology is based on two physical phenomena related to the interaction of the X-ray photons emitted by the capsule with the contents of the colon and the tissue wall.
The number of detected X-ray fluorescence photons and Compton back-scattered photons is correlated to the distance between the capsule and the colon wall. As the distance between the capsule and the colon wall increases, presence of content induces higher rates of X-ray fluorescence photons. At the same time, the content attenuates Compton back-scattered photons, hence decreasing the corresponding detection rate.
The close proximity of the capsule to the scanning target allows for the use of an ultra-low dose radiation, since a very low x-ray flux is required to obtain sufficient signal-to-noise ratio and good scanning quality.
Clinical Study Results For C-Scan in Israel and the EU
In a multi-center, open label prospective study performed in Israel, the C-Scan System demonstrated high sensitivity and specificity for the detection of precancerous polyps when compared to FIT (fecal immunochemical test), a commonly used non-invasive colorectal cancer screening test. Colonoscopy was used as the reference method.
- Sensitivity – ability to correctly identify patients with polyps
- Specificity – ability to correctly identify patients with lack of polyps
U.S. Pilot Trial Results
Publications & Presentations/Events
An x-ray based capsule for colorectal cancer screening incorporating single photon counting technology
The C-Scan System is not approved in the United States and is currently an investigational device there.
The system is approved in the E.U. and Israel but it is not available for sale in any jurisdiction.
This website is not intended to provide medical advice for patients or healthcare providers.